Congress Chairs



Prof. Jacob Schachter, Israel

Prof. Jacob Schachter received his MD in 1976 from the Hebrew University, Hadassah Medical Center, Jerusalem, and was recognized as certified specialist in Oncology in 1987. He is Professor and Head of Oncology Department in Tel-Aviv University Medical School, and director of the Ella Lemelbaum Institute for Immuno-Oncology and Skin Cancer at the Sheba Medical Center in Israel.

He published over 100 original articles in peer reviewed Journals and chapters in books on the subject of melanoma and tumor immunology, and presented his work in many world leading scientific meetings. His current medical and scientific work is concentrated on adoptive immunotherapy of melanoma patients using Tumor Infiltrating Lymphocytes (TIL) Technology, and in clinical development of modern immunotherapy technologies including check-points inhibitors.



Prof. Caroline Robert, France

Prof. Caroline Robert, M.D., Ph.D. is the Head of the Dermatology Service at Gustave Roussy Cancer Campus and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University. She trained at the Paris V University, France and completed a research fellowship at Harvard, Brigham & Women’s hospital in Cancer Immunology and Immunotherapy. She chairs the Melanoma group of the European Organization for the Research and Treatment of Cancer (EORTC) and is board member for the European Association of Onco-Dermatology (EADO), the European Society of Medical Oncology (ESMO), the European Association of Dermato-Venereology (EADV) the French society of Dermatology and Venereology (SFD), the American Society of Oncology (ASCO) and the American Association of Clinical Research (AACR). Her main focuses of interest are clinical and translational Research on Melanoma: immunotherapy and targeted therapy, as well as the study of the cutaneous adverse events of anticancer agents. She is national and international coordinator of many clinical trials of targeted therapy and immunotherapy for melanoma patients, from phase I to III. She has authored more than 240 articles in peer-reviewed scientific journals, including a number of publications on new treatments for metastatic melanoma 

Her recent work has focused on identification of new biomarkers for immunotherapy and targeted therapies of patients with melanoma.